Here are four things to know.
1. The study involved 240 healthy volunteers and was designed to demonstrate the GI safety superiority of ATB-346 compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug in the U.S.
2. ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. While NSAIDs are the most commonly used therapy for osteoarthritis and are widely used in a variety of other conditions, their use is associated with a high incidence of GI ulceration and bleeding.
3. ATB-346 is intended to be an effective, GI-sparing anti-inflammatory/analgesic agent. It is Antibe’s leading drug.
4. Antibe anticipates being able to report top-line results during the week of March 19.
More articles on gastroenterology:
7 statistics on colorectal cancer in the US — 50k+ deaths expected in 2018
The Center for Digestive Health receives ASGE Endoscopy Unit Recognition
4 things to know about the mechanism that may underlie GI, other cancers
